Description: BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Home Page: www.biosenic.com
Building H (box 24)
Mont-Saint-Guibert,
1435
Belgium
Phone:
32 493 09 73 66
Officers
| Name | Title |
|---|---|
| François Rieger | CEO, Pres & Chairman |
| Ms. Véronique Pomi-Schneiter | Deputy CEO & Exec. Director |
| Mr. Michel Wurm M.D. | Interim Chief Medical Officer |
Exchange: BR
Country: BE
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.5329 |
| Price-to-Sales TTM: | 2.3796 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |